Healthcare - Biotechnology - NASDAQ - US
$ 2.47
-4.26 %
$ 51 M
Market Cap
-0.82
P/E
INCOME STATEMENT
0
REVENUE
-43.6 M
OPERATING INCOME
-40.4 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Protara Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 341 K |
| Gross Profit | -341 K |
| Operating Expenses | 43.6 M |
| Operating Income | -43.6 M |
| Other Expenses | -3.19 M |
| Net Income | -40.4 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.9 |
| GROSS PROFIT | ||||||||||
| Cost Of Revenue | 0.3 | 0.2 | 1.2 | 0.2 | 16 K | 0.1 | 0.1 | 0.1 | 57 K | 0 |
| Gross Profit | (0.3) | (0.2) | (1.2) | (0.2) | 16 K | (0.1) | (0.1) | (0.1) | 57 K | 2.9 |
| OPERATING INCOME | ||||||||||
| Operating Expenses | 43.6 | 37.5 | 47.5 | 34.4 | 15.3 | 26.1 | 30.2 | 28.6 | 20.8 | 10.5 |
| Selling, General and Administrative Expenses | 18.6 | 20.7 | 26.4 | 22.5 | 8.8 | 10.6 | 8.5 | 9.7 | 8.4 | 4.1 |
| Research and Development Expenses | 25.0 | 16.8 | 21.1 | 12.0 | 6.4 | 15.5 | 21.7 | 18.9 | 12.4 | 6.4 |
| Operating Income | (43.6) | (67.1) | (47.5) | (34.4) | (15.3) | (26.1) | (30.4) | (28.7) | (20.9) | (7.6) |
| PRE-TAX INCOME | ||||||||||
| Interest Income Expense | 0 | 1.1 | 1.7 | 34 K | 0 | 0 | 0.3 | 0.2 | 0.1 | 0.9 |
| Total Other Income | 3.2 | 1.1 | 0.2 | 0.5 | 0 | 0.6 | 0.4 | 0.2 | (0.5) | 4.2 |
| Pre-Tax Income | (40.4) | (66.0) | (47.3) | (34.0) | (15.0) | (25.4) | (30.0) | (28.5) | (21.4) | (3.3) |
| NET INCOME | ||||||||||
| Tax Provision | 0 | (1.1) | (0.1) | (0.5) | (0.3) | 5.4 | 0.7 | 0.4 | (0.4) | 5.1 |
| Net Income | (40.4) | (64.8) | (47.1) | (33.5) | (14.7) | (25.4) | (30.0) | (28.5) | (21.4) | (3.3) |
| EPS | 3.57 | 5.76 | 4.2 | 4.63 | 229 | 9.93 | 69.4 | 68.9 | 51.9 | 43.6 |